Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

Literature DB >> 3477812

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

R Bernards¹, A Destree, S McKenzie, E Gordon, R A Weinberg, D Panicali.

Abstract

We have constructed a vaccinia virus recombinant that expresses the extracellular domain of the rat neu oncogene-encoded protein, a 185-kDa transmembrane glycoprotein termed p185. Strain NFS mice immunized with this recombinant virus developed a strong antibody response against the neu oncogene product and were fully protected against subsequent tumor challenge with neu-transformed NIH 3T3 cells. No tumor immunoprotection was found when recombinant virus-immunized mice were challenged with Ha-ras-transformed NIH 3T3 cells. These data indicate that immunization with a single oncogene-encoded antigen can fully and specifically protect animals against tumor cells bearing this antigen.

Entities: Disease Gene Species

Mesh：

Year: 1987 PMID： 3477812 PMCID： PMC299183 DOI： 10.1073/pnas.84.19.6854

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

23 in total

1. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus.

Authors: D Panicali; S W Davis; S R Mercer; E Paoletti
Journal: J Virol Date: 1981-03 Impact factor: 5.103

2. pEMBL: a new family of single stranded plasmids.

Authors: L Dente; G Cesareni; R Cortese
Journal: Nucleic Acids Res Date: 1983-03-25 Impact factor: 16.971

3. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors: G L Smith; M Mackett; B Moss
Journal: Nature Date: 1983-04-07 Impact factor: 49.962

4. Clonal cell lines from the rat central nervous system.

Authors: D Schubert; S Heinemann; W Carlisle; H Tarikas; B Kimes; J Patrick; J H Steinbach; W Culp; B L Brandt
Journal: Nature Date: 1974-05-17 Impact factor: 49.962

5. Tumour prevention and rejection with recombinant vaccinia.

Authors: R Lathe; M P Kieny; P Gerlinger; P Clertant; I Guizani; F Cuzin; P Chambon
Journal: Nature Date: 1987 Apr 30-May 6 Impact factor: 49.962

6. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.

Authors: L C Padhy; C Shih; D Cowing; R Finkelstein; R A Weinberg
Journal: Cell Date: 1982-04 Impact factor: 41.582

7. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

Authors: D Panicali; E Paoletti
Journal: Proc Natl Acad Sci U S A Date: 1982-08 Impact factor: 11.205

8. Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors: M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal: Nature Date: 1984 Nov 8-14 Impact factor: 49.962

9. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.

Authors: J R Bennink; J W Yewdell; G L Smith; C Moller; B Moss
Journal: Nature Date: 1984 Oct 11-17 Impact factor: 49.962

10. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

Authors: D Panicali; S W Davis; R L Weinberg; E Paoletti
Journal: Proc Natl Acad Sci U S A Date: 1983-09 Impact factor: 11.205

18 in total

10. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens.

Authors: M L Disis; F M Shiota; M A Cheever
Journal: Immunology Date: 1998-02 Impact factor: 7.397

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

1. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus.

2. pEMBL: a new family of single stranded plasmids.

3. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

4. Clonal cell lines from the rat central nervous system.

5. Tumour prevention and rejection with recombinant vaccinia.

6. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.

7. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

8. Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

9. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells.

10. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

Review 1. The next wave of recombinant and synthetic anticancer vaccines.

2. Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor.

Review 3. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

4. Immunization against endogenous retroviral tumor-associated antigens.

Review 5. Prospects for the therapeutic use of anticancer vaccines.

6. Viral vectors for vaccine applications.

7. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.

Review 8. Cancer vaccines: translation from mice to human clinical trials.

Review 9. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

10. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens.